<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2178">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03078530</url>
  </required_header>
  <id_info>
    <org_study_id>IRB_00059006</org_study_id>
    <nct_id>NCT03078530</nct_id>
  </id_info>
  <brief_title>Probiotic (Visbiome) for Gulf War Illness</brief_title>
  <official_title>Probiotic (Visbiome) for Gulf War Illness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ashok Tuteja</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Salt Lake City Health Care System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective is to determine whether Visbiome will improve

        1. intestinal symptoms of Irritable Bowel Syndrome (IBS) and

        2. non-intestinal symptoms (fatigue, joint pain, insomnia, general stiffness and headache)
           associated with IBS. All of these symptoms are part of the Gulf War (GW) illness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific Aims:

      Aim # 1: Determine the efficacy of Visbiome on IBS symptoms in GW veterans.

      Hypothesis: Treatment with Visbiome compared to placebo will improve global and individual
      symptoms of IBS

      Aim #2 Determine the efficacy Visbiome in reducing non-intestinal symptoms of IBS (fatigue,
      joint pain, insomnia, general stiffness and headache).

      Hypothesis: Treatment with Visbiome compared to placebo will improve non-intestinal symptoms
      of IBS in GW veterans.

      Aim #3 Determine whether changes in gut flora and plasma cytokines correlate with treatment
      response in GW veterans
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 13, 2013</start_date>
  <completion_date type="Anticipated">December 31, 2017</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the bowel symptom scale from the baseline</measure>
    <time_frame>8 weeks</time_frame>
    <description>Efficacy of Visbiome in IBS related symptoms in GW illness is measured using BSS at 2, 4, 6, 8 wks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in chronic fatigue (1-5 scale) from baseline</measure>
    <time_frame>8 weeks</time_frame>
    <description>Efficacy of Visbiome in reducing non-intestinal symptoms of IBS is measured using chronic fatigue scale at 2,4,6,8, weeks.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Gulf War Illness</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (not an active drug/ Inactive component) is given to this group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Visbiome</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Visbiome (probiotic mixture) is given to this group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>This is a pill with inactive ingredients</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo/ Sugar pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Visbiome</intervention_name>
    <description>This is a probiotic mixture</description>
    <arm_group_label>Visbiome</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. First GW veterans, Men and women age 35-75 years,

          2. Rome III criteria for IBS and two or more of the non-intestinal symptoms
             (chronic-once a week or more often-fatigue, joint pains, insomnia, general stiffness,
             and headache)

          3. Symptoms of &gt; 6 months duration,

          4. No significant findings on physical examination, Complete Blood Count (CBC) and
             clinical chemistry panel.

          5. Normal gross appearance of the colonic mucosa other than erythema and polyps

          6. Negative Tissue transglutaminase (TTG) for celiac disease,

          7. Normal thyroid function.

          8. Veterans with psychological disorders will not be excluded but will be identified for
             sub-group analysis.

          9. Stable medication regimen for more than a month

        Exclusion Criteria:

          1. Current evidence of any lower gastrointestinal disorder such as celiac disease or
             inflammatory bowel disease

          2. History of/or presence of systemic malignancy (patients with skin and other cancers
             in remission for more than 5 years are allowed in the study

          3. Clinically significant chronic disease: HIV, cardiac, pulmonary, hepatic or renal
             dysfunction.

          4. Presence of Giardia antigen, and Clostridium difficile toxin in stool,

          5. Abnormal blood test for thyroid stimulating hormone, tissue transglutaminase antibody

          6. Current effects of drug or alcohol abuse

          7. Investigator perception of patient's inability to comply with study protocol

          8. Recent change in gastrointestinal medications

          9. Use of any antibiotic in the last 1 months

         10. Positive pregnancy test

         11. Subject is currently participating in another research protocol that could interfere
             or influence the outcome measures of the present study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashok Tuteja, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>George E Wahlen VA Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashok Tuteja, MD, MPH</last_name>
    <phone>8015821565</phone>
    <phone_ext>4019</phone_ext>
    <email>ashok.tuteja@va.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jaya Vijayan, MBBS</last_name>
    <phone>8015821565</phone>
    <phone_ext>4672</phone_ext>
    <email>jaya.vijayan@va.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>George E Wahlen VA Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84148</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashok Tuteja, , MD, MPH</last_name>
      <phone>801-582-1565</phone>
      <phone_ext>4019</phone_ext>
      <email>ashok.tuteja@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Jaya Vijayan, MBBS</last_name>
      <phone>8015821565</phone>
      <phone_ext>4672</phone_ext>
      <email>jaya.vijayan@va.gov</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 10, 2017</lastchanged_date>
  <firstreceived_date>March 8, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>VA Salt Lake City Health Care System</investigator_affiliation>
    <investigator_full_name>Ashok Tuteja</investigator_full_name>
    <investigator_title>Professor Gastroenterology</investigator_title>
  </responsible_party>
  <keyword>GWI</keyword>
  <keyword>IBS</keyword>
  <keyword>Irritable Bowel Syndrome</keyword>
  <keyword>Gulf War Illness</keyword>
  <keyword>Probiotics</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
